

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MedSci Healthcare Holdings Limited**

### **梅斯健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2415)**

## **VOLUNTARY ANNOUNCEMENT ENTRY OF STRATEGIC COOPERATION BETWEEN VALLEY BIO AND WEIGAO HOLDING**

This voluntary announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide the shareholders and potential investors of the Company with the latest business development of the Group.

The Company is pleased to announce that recently, Shanghai Chungu Bio Medicine Technology Co., Ltd. (上海春谷生物醫藥科技有限公司) (the “**Valley Bio**”), a subsidiary of the Company, has officially entered into strategic cooperation with Weigao Holding Co., Ltd. (威高集團有限公司) (the “**Weigao Holding**”). Both parties will make synergetic efforts to stimulate more innovative vitality at the local level, and deepen the promotion of the influence of Weigao Park (威高園區) and high-quality products of Weigao Holding through media cooperation and promotion, industrial park investment promotion, as well as joint efforts to foster multiple alliance models, including strategic service alliance for industry sharing and exchange, strategic alliance for market acceleration services, technology research and innovation alliance, and financial service innovation alliance. Such cooperation will enable Weigao Holding to continue improving its core industrial competitiveness.

### **REASONS FOR AND BENEFITS OF COOPERATION**

With the Chinese healthcare industry currently embracing the digital intelligence transformation initiative, MedSci Healthcare, as a leader in healthcare digitalization and smartisation in the PRC, has consistently upheld its mission and vision of “improving medical quality”, by providing precision digital and smart medicine through the utilisation of big data and artificial intelligence. The MedSci platform has already accumulated 5.1 million registered members, including 3.1 million certified

physician users. By leveraging immense resources available at our physician platform, pharmaceutical and medical device companies will be empowered with precision omnichannel marketing.

Weigao Holding is principally engaged in medical devices and pharmaceuticals, and boasts 13 industry clusters and over 100 subsidiaries, including three listed companies and eight overseas entities. It has established 15 national and provincial innovation platforms, such as a nationally recognized enterprise technology centre (國家認定企業技術中心), national engineering research centre (國家工程研究中心), national pilot innovation enterprise (全國創新試點型企業), academician workstations (院士工作站), postdoctoral workstations (博士後工作站), and the Taishan Scholar Laboratory (泰山學者實驗室). MedSci Healthcare wishes to fully avail this opportunity of cooperation by focusing on each other's strengths and matching professional resources so as to provide innovative solutions to Weigao Holding across a number of segments, including industry exchanges, media promotion, research and innovation, and financial service innovation. In return, such cooperation will advance the digital intelligence transformation and intelligent upgrade in the healthcare industry.

Looking into the future, MedSci Healthcare will persistently maintain medical expertise and digitalization as the dual core genes of MedSci. Based on professional medical information, precision digitalization technology, and their full and effective integration, the Company will work with industry peers to establish an ecosystem where the imbalances will be eliminated, empowering the high-quality development of the entire medical and pharmaceutical industry, eventually leading to a better life.

By order of the Board  
**MedSci Healthcare Holdings Limited**  
**梅斯健康控股有限公司**

**Dr. Zhang Fabao**  
*Chairman of the Board and Executive Director*

Hong Kong, 19 July 2024

*As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.*